Indian Stock NSE ,MCX,Ncdex,Forex,Comex Mareket Updates

A Comprehensive Technical Analysis Programmes aimed to make you a Profitable Trader and achieve 100% return per annum on your Investment IN MCX & STOCK MARKET SPECIALLY IN GOLD MARKET

TRAINING IS GOING ON TAMILNADU, KERALA,KARNATAKA MORE DETAILS@09952833280/09042689098

In1978 sensex @100 after 10years in 1988 100*6 sensex @600 in 1998 600*6 sensex@3600 in 2008 3600*6 sensex@21600 then in 2018 sensex 129600......
A Comprehensive Technical Analysis Programmes aimed to make you a Profitable Trader and achieve 100% return per annum on your Investment IN MCX & STOCK MARKET SPECIALLY IN GOLD MARKET


No one beat our accuracy, Still why u r waiting? join us. Grow with Us with profit.Our clients made massive profit with our calls

If U Want Nifty & Stock Option calls &MCX & NCDEX COMMODITY daily ADD me On JANURAM@GMAIL.COM & JMSQUARENIFTY@yahoo.com & JMSQUARENIFTYGOLD@yahoo.com Contact Me@9952833280&9042689098


Disclaimer

Ours is an advisory role. The final decision and consequences based on our Information is solely yours. Moreover, in keeping with regulatory guidelines, we do not guarantee any returns on investments. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.


2008-07-29

Soon, vaccine against bio weapons

Experts at the Society for General Microbiology have made a significant advance towards making a vaccine against an organism that may be used to produce biological weapons.


Writing about their achievement in the Journal of Medical Microbiology, the researchers have revealed that they have made a rapid progress in understanding how the pathogen Francisella tularensis causes disease.


"Only very few bacteria are needed to cause serious disease," said Prof Petra Oyston from Dstl, Porton Down.


"Because of this and the fact that tularemia can be contracted by inhalation, Francisella tularensis has been designated a potential biological weapon. Since the events of September 2001 and the subsequent anthrax attacks on the USA, concern about the potential misuse of dangerous pathogens including F. tularensis has increased. As a result, more funding has been made available for research on these organisms and has accelerated progress on developing medical countermeasures," the researchers added.


Tularemia circulates in rodents and animals like rabbits and hares, and outbreaks in humans often happen at the same time as outbreaks in these animals.


The disease is probably transmitted by insects like mosquitoes, ticks, and deer flies.


People can also become infected by contact with contaminated food or water and by breathing in particles containing the bacteria.


Farmers, hunters, walkers and forest workers are most at risk of contracting tularemia.


The researchers say that research into F. tularensis’s pathogenesis attains significance in view of the fact that various nations have developed it as a biological weapon, and also because some are said to have produced antibiotic-resistant strains.


"Progress is being made. Since the genome of F. tularensis was sequenced, researchers have taken great strides in understanding the molecular basis for its pathogenesis. This is essential information for developing a vaccine and getting it licensed," said Prof. Oyston.


The researchers, however, concede that they are still unsure about the function of most F. tularensis genes.


"Recently genes needed by F. tularensis for growth and survival have been identified. These could be targets for novel antimicrobial development or could be used in the production of a vaccine," said Prof. Oyston.


"Although we are getting closer to addressing key issues such as the need for an effective vaccine, it appears we are still some way from understanding the pathogenesis of F. tularensis. More research is needed in this area," Prof. Oyston added.

No comments:

Disclaimer

Ours is an advisory role. The final decision and consequences based on our Information is solely yours. Moreover, in keeping with regulatory guidelines, we do not guarantee any returns on investments. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.